Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alterity Therapeutics (ATHE) Change in Accured Expenses (2016 - 2020)

Alterity Therapeutics has reported Change in Accured Expenses over the past 4 years, most recently at $27375.1 for Q4 2018.

  • For Q4 2018, Change in Accured Expenses fell 68.43% year-over-year to $27375.1; the TTM value through Dec 2018 reached $180295.0, up 11.77%, while the annual FY2019 figure was $33175.8, 4125.31% up from the prior year.
  • Change in Accured Expenses for Q4 2018 was $27375.1 at Alterity Therapeutics, up from -$824.18 in the prior quarter.
  • Over five years, Change in Accured Expenses peaked at $86708.3 in Q4 2017 and troughed at -$9017.2 in Q2 2016.
  • A 4-year average of $31309.3 and a median of $21976.6 in 2015 define the central range for Change in Accured Expenses.
  • Biggest five-year swings in Change in Accured Expenses: skyrocketed 843.42% in 2017 and later crashed 101.23% in 2018.
  • Year by year, Change in Accured Expenses stood at $16578.1 in 2015, then tumbled by 154.39% to -$9017.2 in 2016, then soared by 1061.59% to $86708.3 in 2017, then crashed by 68.43% to $27375.1 in 2018.
  • Business Quant data shows Change in Accured Expenses for ATHE at $27375.1 in Q4 2018, -$824.18 in Q2 2018, and $86708.3 in Q4 2017.